Pandher et al. reported that the MYCN selective inhibitor M606 reduced N-Myc levels by binding to its promoter, upregulated hypoxia-inducible factor 1 alpha (HIF1A), and delayed the progression of NB in TH-MYCN mice (Pandher et al., 2025). Here, HIF1A is linked to neuroblastoma.